Canagliflozin alleviates high glucose-induced peritoneal fibrosis via HIF-1 α inhibition
In conclusion, we showed that Canagliflozin could improve peritoneal fibrosis and function by ameliorating peritoneal hypoxia and inhibiting the Hif-1α/TGF-β/p-Smad3 signaling pathway, providing theoretical support for the clinical use of SGLT2 inhibitors in patients on peritoneal dialysis.
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
More News: Canagliflozin | Cardiology | Dialysis | Drugs & Pharmacology | Heart | Invokana | Peritoneal Dialysis | SGLT2 Inhibitors | Sodium | Study | Urology & Nephrology